Engineering any genome, at any site, in any way
At the forefront of a revolutionary field offering profound benefits to human health and society
Focused on the advancement of new applications for CRISPR-based technologies
Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech
Caribou Biosciences’ President and CEO Rachel Haurwitz Named to Fortune’s 2016 “40 under 40” List of Most Influential Young People in BusinessSeptember 26, 2016
Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing. Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole.
Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.